Обзор исследований по безопасности Максаквина

1. Структура и антибактериальная активность Максакпипа / / Пульмонология.— 1993.— П рилож ение 1. —

2. Фармакоки нетические свойства Максаквипа / / Там же. —

3. Применение Максаквипа при лечении и профилактике инфекций мочевыводящих путей / / Там же.

4. Максаквин при лечении обострений хронического бронхита / / Там же.

5. Клиническая эффективность Максаквипа / / Там же.

6. Rizk Е. A worldwide clinical overview of lomefloxacin, a oncedaily fluoroquinolone / / Int. J. Antimicrob. Agents.— 1992.— Vol.' 2 .— P. 67— 78.

7. Bednarczyk E .M ., Green J.A ., N elson A.D. et al. Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen m etabolism in healthy subjects by positron emission tomography / / Pharmacotherapy.— 1992.— Vol. 12.— P. 369— 375.

8. . Ed lund C., Brismar B., Nord C.E. Effect of lomefloxacin on the normal oral and intestinal microflora / / Eur. J. Clin. Microbiol. Infect. Dis.— 1990.— Vol. 9.— P. 35— 39.

9. Inagaki Y., Chid a T .t Nakaya R. et al. Effect of N Y -198, a new quinolone derivative, on human intestinal microflora / / Chemotherapy (Tokyo). — 1988.— Vol. 36, Suppl.2.— P. 120— 131.

10. Leigh D .A., Harris C., Tail S. et al. Pharm ocokinetic study of lomefloxacin and its effect on the faecal flora of volunteers / / J. Antimicrob. Chemother.— 1991.— Vol. 27. P. 655— 662.

11. Shim o Т., Matsuda K., Sailo A ., Yamazaki M . Arthrotoxicity study of NY -198 in rats / / Chemotherapy (Tokyo).— 1988.— Vol. 36, Suppl.2.— P. 439— 448.

12. Tesh J.M ., McAnully P .A ., W illoughby C.R. et al. Reproductive studies of N Y -198 in rats. I. Fertility studv / / Jpn. J. Antibiot.— 1988.— Vol. 41.— P. 1341 — 135L

13. Tesh J.M ., McAnulty P .A ., Willoughby C.R. et al. Reproductive studies of NY-198 in rats. II. Teratology studv / / Ibid.— P. 1352— 1369.

14. Tesh J.M ., McAnully P .A ., Willoughby C.R. et al. Reproductive studies of N Y -198 in rats. III. Perinatal and postnatal study / / Ibid.— P. 1370— 1384.

15. UmemuraT., Sasa lL , Iizuka T ., YanagitaT. Teratalogical study of oral administration of N Y -198 in rabbits / / Chemotherapy (Tokyo).— 1988.— Vol. 36, Suppl.2.— P. 391— 410.

16. Yamamoto K .-J.t Naitoh Y., Inone Y. et al. Seizure discharges induced by the combination of a new quinolinecarboxylic acid antimicrobial drugs and non-steroidal anti-inflammatory drugs. Effect of NY-198 on the central nervous system V / Ibid.— P. 300— 324.

17. Symonds W .T., Nix D.E. Lomefloxacin and temafloxacin: two new fluoroquinolone antim icrobials / / Clin. Pharm .— 1992.— Vol. 11.— P. 753— 766.

18. Campoli-Richards D .M ., Monk J.P ., Price A. el al. Ciprofloxacin. A review of its antibacterial activity, pharm acokinetic properties and therapeutic use / / Drugs.— 1988.— Vol. 35.— P. 373— 447.

19. Arcieri G., Griffith E., Gruenwaldt G. et al. Ciprofloxacin: an update on clinical experience / / Am. J. Med.— 1987. Vol. 82, Suppl.4A .— P. 381— 386.

20. Ball P. Ciprofloxacin: an overview of adverse experiences / / J. Antimicrob. Chemother.— 1986.— Vol. 18, Suppl.D.— P. 187— 193

21. Wang C., Sabbaj J., Corrado М ., Iloagland V. World-wide clinical experience with norfloxacin efficacy and safely / / Scand. J. Infect. Dis.— 1986.— Vol. 48, Suppl.— P. S I — S9.

22. Blom er R., Bruch K., Krauss II., W acheck W. Safely of ofloxacin— adverse drug reactions reported during phase-II studies in Europe and in Japan / / Infection.— 1986.— Vol. 14, Suppl.4.— P. S332— S334.

23. Smith C.R. The adverse effects of fluoroquinolones III. Antimicrob. Chemother.— 1987.— Vol. 19.— P. 709— 711.

24. Ilalkin II. Adverse effects of the fluoroquinolones / / Rev. Infect. Dis.— 1988.— Vol. 10, Suppl.1.— P. S258— S261.

25. Tatsum i II., Senda II., Yatera S. et al. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals / / J. Tox. Sci.— 1978.— Vol. 3.— P. 357— 367.

26. Schlufer G. Ciprofloxacin: review of potential toxicologic effects / / Am. J. Med.— 1987.— Vol. 82., Suppl.4A .— P. 91— 93.

27. Schluter G. Toxicology of quinolones / / Forlschr. antim ikn antincoplast. Chemother.— 1987.— N 6— 10.— S. 1631 — 1642.

28. Christ W ., Lehnert Т., Ulbrich B. Specific toxicologic aspects of the quinolones / / Rev. Infect. Dis.— 1988.— Vol. 10, Suppl. 1.— P. S141— S146.

29. Stahlmann R ., Lode II. Safety overview: toxicity, adverse effects and drug interactions / / The Quinolones / Ed. V.T. Andriole.— New York: Academic Press, 1988.— P. 201— 233.

30. Stahlmann R. Safety profile of the quinolones / / J. Antimicrob. Chemother.— 990'.— Vol. 26, Suppl.D .— P. 31— 44.

31. Gleckm an R., A lvarez S., Joubert D.W ., Matthews S.J. Drug therapy reviews: nalidixic acid / / Am. J. IIosp. P harm .— 1979.— Vol. 36.— P. 1071 — 1076.

32. Simpson K .J., Brodie M .J. Convulsions related to cnoxacin / / Lancet.— 1985.— Vol. 2.— P. 161.

33. AnastasioG .D ., MenscerD ., Little J.M . Jr. Norfloxacin and seizures / / Ann. Intern. Med.— 1988.— Vol. 109.— P. 169— 170.

34. Lucet J.-C ., Tilly II., Lerebours G. et al. Neurological toxicity related to pefloxacin III. Antimicrob. C hem other.— 1988.— Vol. 21.— P. 811— 812.

35. Tsuji A., Sato II., К ите Y. et al. Inhibitory effects of quinolone antibacterial agents on -am inobutyric acid binding to receptor sites on rat brain m embranes / / Antimicrob. Agents Chem other.— 1988.— Vol. 32.— P. 190— 194.

36. Akahane K., Sekiguchi М ., Une Т., Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with -am inobutyric acid receptor sites / / Ibid.— 1989.— Vol. 33.— P. 1704— 1708.

37. Segev S., RehaviM ., Rubinstein E. Quinolones, theophylline and diclofenac interactions with the aminobutyric acid receptor / / Ibid.— 1988.— Vol. 32.— P. 1624— 1626.

38. Thorsteinsson S.B., Bergan Т., Oddsdoltir S. et al. C rystalluria and ciprofloxacin, influence of urinary pH and hydration / / Chemoterapy (B asel).— 1986.— Vol. 32.— P. 408— 417.